OS Therapies Incorporated (OSTX) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
OS Therapies Incorporated (OSTX) Earnings Overview
As of June 28, 2026, OS Therapies Incorporated (OSTX) reported trailing twelve-month net income of -$35M, reflecting -88.5% year-over-year growth. The company earned $-0.91 per diluted share over the past four quarters.
Looking at the long-term picture, OSTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$6,027 in fiscal 2020.
OS Therapies Incorporated is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), RCKT (-$209M net income), FATE (-$130M net income, -2051.1% margin), OSTX has comparable earnings metrics. Compare OSTX vs IMVT →
OSTX Earnings vs Peers
Earnings metrics vs comparable public companies
OSTX Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$29M | -223.7% | -$29M | $-0.98 | - | - |
| 2024 | -$9M | -14.0% | -$7M | $-0.52 | - | - |
| 2023 | -$8M | -24.6% | -$4M | $-0.39 | - | - |
| 2022 | -$6M | +15.7% | -$4M | $-0.28 | - | - |
| 2021 | -$7M | -123016.8% | -$5M | $-0.33 | - | - |
| 2020 | $-6,027 | - | $-5,647 | $-0.00 | - | - |
Download Data
Export OSTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
OSTX — Frequently Asked Questions
Quick answers to the most common questions about buying OSTX stock.
What is OSTX earnings per share (EPS)?
OSTX trailing twelve-month (TTM) diluted EPS is $-0.91, reflecting -88.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is OS Therapies Incorporated's net income?
OS Therapies Incorporated (OSTX) trailing twelve-month net income is $-35M as of 2025. Earnings declined -88.5% year-over-year.
Is OSTX profitable?
OSTX is not currently profitable on a TTM basis, reporting a net loss of $-35M. Net margin is N/A. Investors should monitor for a return to profitability.
What is OSTX's earnings growth rate?
OSTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are OSTX's profit margins?
OS Therapies Incorporated net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is OSTX growing earnings?
OSTX earnings are declining — EPS fell -88.5% year-over-year. TTM net income dropped to $-35M. This contrasts with the 5-year CAGR of N/A.
What was OSTX's best earnings year?
OS Therapies Incorporated's highest annual net income on record is $-6027.00, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were OSTX's earnings last quarter?
OSTX's most recent reported quarter was Q1 2026. Net income was $-10M with diluted EPS of $-0.27. For a full breakdown of all quarters, see the quarterly earnings table on this page.